


8-20-07

15w

**IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE**

Serial No. : 10/525,986  
Applicants : Tadashi NAKAJIMA et al.  
Filed : February 25, 2005  
For : THERAPEUTIC AGENT FOR  
GLAUCOMA COMPRISING Rho  
KINASE INHIBITOR AND  
PROSTAGLANDIN  
Patent Unit : 1618  
Examiner : Zohreh FAY  
Docket No. : 05116/HG  
Confirm No. : 5004  
Customer No.: 01933



Express Mail Mailing Label  
No.: EM 155 716 583 US  
Date of Deposit: August 16, 2007  
I hereby certify that this paper is  
being deposited with the United States  
Postal Service "Express Mail Post  
Office to Addressee" service under  
37 CFR 1.10 with sufficient postage  
on the date indicated above and is  
addressed to:  
MAIL STOP AMENDMENT  
Commissioner for Patents,  
P.O. Box 1450  
Alexandria, VA 22313-1450

*Dorothy DeFrancesco*  
Dorothy DeFrancesco

In the event that this Paper is late  
filed, and the necessary petition  
for extension of time is not filed  
concurrently herewith, please consider  
this as a Petition for the requisite  
extension of time, and to the extent  
not tendered by Form PTO-2038 attached  
hereto, authorization to charge the  
extension fee, or any other fee  
required in connection with this  
Paper to Account No. 06-1378.

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**MAIL STOP AMENDMENT**

S I R :

Submitted concomitantly herewith are the following:

- (1) A copy of a Supplementary Partial European Search  
Report, which issued in the counterpart European application;
- (2) IDS Forms. It is respectfully requested that initialed  
copies of the enclosed IDS Forms be returned to the undersigned  
to indicate that the publications listed therein have been  
considered and made of record; and

(3) Copies of the non-U.S. patent documents cited in said IDS Forms.

Each of the cited publications, which are disclosed in the enclosed Search Report, is considered relevant or material to the patentability of the present claims in view of the citation thereof in said Search Report.

Said Search Report is in English, thereby satisfying the requirements for a concise explanation of relevance for the publications cited therein.

The following publication, which was cited in the enclosed Supplementary Partial European Search Report, was cited in the INFORMATION DISCLOSURE STATEMENT dated May 16, 2005:

HONJO MEGUMI et al., "Effects of Rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility," Investigative Ophthalmology & Visual Science, Association for Research in Vision, Vol. 42, No. 1, January 2001, pp. 137-144.

The following is a copending related application: Serial No. 10/535,000 (published as US 2006/0052367).

The enclosed IDS Forms include publications cited in  
application Serial No. 10/535,000.

Respectfully submitted,



RICHARD S. BARTH  
REG. NO. 28,180


FRISHAUF, HOLTZ, GOODMAN & CHICK, P.C.  
220 FIFTH AVENUE, 16th FLOOR  
NEW YORK, NEW YORK 10001-7708  
Tel. Nos. (212) 319-4900  
(212) 319-4551/Ext. 219  
Fax No. (212) 319-5101  
E-Mail Address: BARTH@FHGC-LAW.COM  
RSB/ddf

- Encs.: (1) copy of Supplementary Partial European Search Report  
dated June 6, 2007
- (2) IDS Forms
- (3) copies of the non-U.S. patent documents cited on the  
enclosed IDS Forms

Please type a plus sign (+) inside this box →

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



IDS FORM

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Application Number	10/525,986
Filing Date	February 25, 2005
First Named Inventor	Tadashi NAKAJIMA
Group Art Unit	1618
Examiner Name	Zohreh FAY
Attorney Docket Number	05116/HG

Sheet

1

of

3

### U.S. PATENT DOCUMENTS

Exam. Inits*	Cite No <sup>1</sup>	Document Number	Kind Code <sup>2</sup>	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
/S.B./		2006/0052367	A1	HATANO et al.	03-09-2006	

### FOREIGN PATENT DOCUMENTS

Exam. Inits*	Cite No <sup>1</sup>	Offc <sup>3</sup>	Document Number <sup>4</sup>	Kind Code <sup>5</sup>	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T <sup>6</sup>
/S.B./		WO	00/25771	A1	SYNPHORA AB	05-11-2000		
/S.B./		WO	00/57914	A1	SANTEN PHARMACEUTICAL CO LTD	10-05-2000		a
/S.B./		WO	93/16701	A2	ALCON LABORATORIES INC	09-02-1993		
/S.B./		WO	03/049745	A1	PHARAMCIA CORP	06-19-2003		

Examiner  
Signature

Date  
Considered

\* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Place a check here if English translation is attached.

DATE: August 16, 2007

a ENGLISH-LANGUAGE ABSTRACT ENCLOSED

Please type a plus sign (+) inside this box →



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b>IDS FORM</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/525,986
				Filing Date	February 25, 2005
				First Named Inventor	Tadashi NAKAJIMA
				Group Art Unit	1618
				Examiner Name	Zohren FAY
Sheet	2	of	3	Attorney Docket Number	05116/HG

**OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/S.B./		ZHOU YAN et al., "Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic A $\beta$ <sub>42</sub> by Inhibiting Rho," <u>Science</u> , Vol. 302, no. 5648, 14 November 2003, pp. 1215-1217	
/S.B./		HONJO et al., "Effects of Protein Kinase Inhibitor, HA1077, on Intraocular Pressure and Outflow Facility in Rabbit Eyes," <u>Archives of Ophthalmology</u> , Vol. 119, no. 8, August 2001, pp. 1171-1178	
/S.B./		DATABASE WPI Week 200060, Derwent Publications Ltd., London, GB; AN 2000-628321 of WO 00/57914 (Santen Pharmaceutical Co., Ltd.; Oct. 5, 2002)	
/S.B./		CLARK A.F. et al., "Advances in Glaucoma Therapeutics," <u>Expert Opinion of Emerging Drugs</u> , 2002, United Kingdom, Vol. 7, no. 1, May 2002, pp. 141-163	
/S.B./		UEHATA M. et al., "Calcium Sensitization of Smooth Muscle Mediated by a Rho-Associated Protein Kinase in Hypertension," <u>Nature</u> , Vol. 389, October 1997, pp. 990-994	
		Mariko ASAHII et al., "Ryokunaisho to Ryokunaisho Chiryo Yakuzai (Fukuyaki Shido Manual II, Dai 10 Kai)," <u>The Pharmaceuticals Monthly</u> , (1996), 38(9), pp. 2311 to 2331	
		Kuniteru SHIRATO, "I. Ryokunaisho no Yakubutsu Ryoho 1. Gairon" (Chiryoyaku no Sentaku 1. Bon Kangaerunoka) / <u>Some Practical Aspect in medical therapy</u> , <u>Ganka</u> , (2002), 44(11), pp. 1443 to 1448	
		Tatsuro FUKUCHI, "I. Ryokunaisho no Yakubutsu Ryoho 2. Ryokunaisho Chiryoyaku C. Kokan Shinhai Sogaiyaku 3. Shadenyaku" ( <u><math>\beta</math>-Adrenergic Antagonists</u> ) <u>Ganka</u> , (2002), 44(11), pp. 1458 to 1463	
/S.B./		Yuichiro OTAKE et al., "Effect and Safety of Combined Therapy with Betaxolol and isopropyl Unoprostone," <u>The Journal of the Eye</u> , (2000), 17(5), pp. 687 to 690	
Examiner Signature		Date Considered	

\* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Place a check here if English translation is attached.

DATE: August 16, 2007

Please type a plus sign (+) inside this box →



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b>IDS FORM</b>  <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>				Application Number	10/525,986
				Filing Date	February 25, 2005
				First Named Inventor	Tadashi NAKAJIMA
				Group Art Unit	1618
				Examiner Name	Zohreh FAY
Sheet	3	of	3	Attorney Docket Number	05116/HG

**OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Hideki TOKUSHIGE, "ROCK Sogaiyaku to Ryokunaisho" ("ROCK Inhibitor and Glaucoma"), <u>BIO Clinica</u> , (2002), 17(13), pp. 1191 to 1194.	
/S.B./		HOYNG, P.F.J. et al., "Pharmacological Therapy for Glaucoma," <u>Drugs</u> , (2000), 59(3), pp. 411 to 434.	
/S.B./		Ikuo AZUMA et al., "Effects of Bunazosin Hydrochloride Ophthalmic Solution in Combination with Timolol Maleate Ophthalmic Solution in Patients with Open-Angle Glaucoma and Ocular Hypertension-Comparison with Dipivefrin Hydrochloride Ophthalmic Solution," <u>The Journal of the Eye</u> , (2002), 1992), pp. 261-266	
/S.B./		Marie A. ABATE et al., "Effect of Naproxen and Sulindac on Blood Pressure Response to Atenolol," <u>DICP - ANNALS OF PHARMACOTHERAPY</u> , Vol. 24, no. 9, 1990, pp. 810-813	
Examiner Signature		/Sean Basquill/	Date Considered
			07/16/2008

\* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Place a check here if English translation is attached.

DATE: August 16, 2007

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.B./